352 related articles for article (PubMed ID: 25010764)
1. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
Márk Á
Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
[TBL] [Abstract][Full Text] [Related]
2. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.
Márk Á; Hajdu M; Váradi Z; Sticz TB; Nagy N; Csomor J; Berczi L; Varga V; Csóka M; Kopper L; Sebestyén A
BMC Cancer; 2013 May; 13():250. PubMed ID: 23693095
[TBL] [Abstract][Full Text] [Related]
3. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
4. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
Nagy N; Hajdu M; Márk Á; Király PA; Tóth M; Dankó T; Csóka M; Sebestyén A
Tumour Biol; 2016 Oct; 37(10):13695-13704. PubMed ID: 27473087
[TBL] [Abstract][Full Text] [Related]
6. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.
Gupta M; Hendrickson AE; Yun SS; Han JJ; Schneider PA; Koh BD; Stenson MJ; Wellik LE; Shing JC; Peterson KL; Flatten KS; Hess AD; Smith BD; Karp JE; Barr S; Witzig TE; Kaufmann SH
Blood; 2012 Jan; 119(2):476-87. PubMed ID: 22080480
[TBL] [Abstract][Full Text] [Related]
7. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin can restore the negative regulatory function of transforming growth factor beta 1 in high grade lymphomas.
Sebestyén A; Márk Á; Hajdu M; Nagy N; Molnár A; Végső G; Barna G; Kopper L
Cytokine; 2015 Jun; 73(2):219-24. PubMed ID: 25794661
[TBL] [Abstract][Full Text] [Related]
9. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
[TBL] [Abstract][Full Text] [Related]
10. Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study.
Sebestyén A; Sticz TB; Márk A; Hajdu M; Timár B; Nemes K; Nagy N; Váradi Z; Kopper L
Mod Pathol; 2012 Dec; 25(12):1623-8. PubMed ID: 22899290
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.
Gupta M; Ansell SM; Novak AJ; Kumar S; Kaufmann SH; Witzig TE
Blood; 2009 Oct; 114(14):2926-35. PubMed ID: 19641186
[TBL] [Abstract][Full Text] [Related]
12. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
13. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
[TBL] [Abstract][Full Text] [Related]
14. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW
Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668
[TBL] [Abstract][Full Text] [Related]
15. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.
Redaelli S; Ceccon M; Antolini L; Rigolio R; Pirola A; Peronaci M; Gambacorti-Passerini C; Mologni L
Oncotarget; 2016 Nov; 7(45):72886-72897. PubMed ID: 27662658
[TBL] [Abstract][Full Text] [Related]
16. Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma.
Xu ZZ; Wang WF; Fu WB; Wang AH; Liu ZY; Chen LY; Guo P; Li JM
Leuk Lymphoma; 2014 May; 55(5):1151-7. PubMed ID: 23841505
[TBL] [Abstract][Full Text] [Related]
17. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.
Quesada AE; Nguyen ND; Rios A; Brown RE
Int J Clin Exp Pathol; 2014; 7(12):8732-9. PubMed ID: 25674239
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
19. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
20. 4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.
Yun S; Vincelette ND; Knorr KL; Almada LL; Schneider PA; Peterson KL; Flatten KS; Dai H; Pratz KW; Hess AD; Smith BD; Karp JE; Hendrickson AE; Fernandez-Zapico ME; Kaufmann SH
Blood; 2016 Jun; 127(22):2711-22. PubMed ID: 26917778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]